世界の非腫瘍学バイオ医薬品市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Non-oncology Biopharmaceuticals Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-5893
• 出版社/出版日：QYResearch / 2021年6月
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、126ページ
• 納品方法：Eメール（納期：3日）
• 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥585,000 (USD3,900)	▷ お問い合わせ
Multi User	￥877,500 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

QYResearch社発行の本調査レポートでは、非腫瘍学バイオ医薬品の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（生物製剤、バイオシミラー）、用途別市場規模（免疫、内分泌、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。
・市場概要
・非腫瘍学バイオ医薬品の市場動向
・企業の競争状況、市場シェア
・非腫瘍学バイオ医薬品の種類別市場規模と予測2016-2027（生物製剤、バイオシミラー）
・非腫瘍学バイオ医薬品の用途別市場規模と予測2016-2027（免疫、内分泌、その他）
・非腫瘍学バイオ医薬品の北米市場規模2016-2027（アメリカ、カナダ）
・非腫瘍学バイオ医薬品の欧州市場規模2016-2027（ドイツ、フランス、イギリス等）
・非腫瘍学バイオ医薬品のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等）
・非腫瘍学バイオ医薬品の中南米市場規模2016-2027（メキシコ、ブラジル）
・非腫瘍学バイオ医薬品の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等）
・主要企業情報（Roche、Sanofi、Johnson & Johnson、Pfizer、Novo Nordisk、Novartis、Merck、Teva、Eli Lilly、Bristol-Myers Squibb、GlaxoSmithKline、UCB Pharma、Amgen、AbbVie、Takeda、AstraZeneca、Mylan、LEO Pharma、Boehringer Ingelheim、Alexion Pharmaceuticals、Elusys Therapeutics、Swedish Orphan Biovitrum、Biogen）
・結論

Biopharmaceutical, also known as a biologic (al) medical product, biological, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semi synthesized from biological sources. Different from totally synthesized pharmaceuticals, they include vaccines, blood, blood components, allergenic, somatic cells, gene therapies, tissues, recombinant therapeutic protein, and living cells used in cell therapy. Biologics can be composed of sugars, proteins, or nucleic acids or complex combinations of these substances, or may be living cells or tissues. They (or their precursors or components) are isolated from living sources—human, animal, plant, fungal, or microbial. This report studies Non-oncology biopharmaceutical which are the drugs that are used in the treatment of various diseases rather than cancer.

Market Analysis and Insights: Global Non-oncology Biopharmaceuticals Market
The global Non-oncology Biopharmaceuticals market size is projected to reach US$ 531430 million by 2027, from US$ 295620 million in 2020, at a CAGR of 8.3% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Non-oncology Biopharmaceuticals market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Non-oncology Biopharmaceuticals market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Non-oncology Biopharmaceuticals market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Non-oncology Biopharmaceuticals market.

Global Non-oncology Biopharmaceuticals Scope and Market Size
Non-oncology Biopharmaceuticals market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Non-oncology Biopharmaceuticals market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Biologics
Biosimilars

Segment by Application
Immunology
Endocrinology
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Roche
Sanofi
Johnson & Johnson
Pfizer
Novo Nordisk
Novartis
Merck
Teva
Eli Lilly
Bristol-Myers Squibb
GlaxoSmithKline
UCB Pharma
Amgen
AbbVie
Takeda
AstraZeneca
Mylan
LEO Pharma
Boehringer Ingelheim
Alexion Pharmaceuticals
Elusys Therapeutics
Swedish Orphan Biovitrum
Biogen

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-oncology Biopharmaceuticals Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Biologics
1.2.3 Biosimilars
1.3 Market by Application
1.3.1 Global Non-oncology Biopharmaceuticals Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Immunology
1.3.3 Endocrinology
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Non-oncology Biopharmaceuticals Market Perspective (2016-2027)
2.2 Non-oncology Biopharmaceuticals Growth Trends by Regions
2.2.1 Non-oncology Biopharmaceuticals Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Non-oncology Biopharmaceuticals Historic Market Share by Regions (2016-2021)
2.2.3 Non-oncology Biopharmaceuticals Forecasted Market Size by Regions (2022-2027)
2.3 Non-oncology Biopharmaceuticals Industry Dynamic
2.3.1 Non-oncology Biopharmaceuticals Market Trends
2.3.2 Non-oncology Biopharmaceuticals Market Drivers
2.3.3 Non-oncology Biopharmaceuticals Market Challenges
2.3.4 Non-oncology Biopharmaceuticals Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Non-oncology Biopharmaceuticals Players by Revenue
3.1.1 Global Top Non-oncology Biopharmaceuticals Players by Revenue (2016-2021)
3.1.2 Global Non-oncology Biopharmaceuticals Revenue Market Share by Players (2016-2021)
3.2 Global Non-oncology Biopharmaceuticals Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Non-oncology Biopharmaceuticals Revenue
3.4 Global Non-oncology Biopharmaceuticals Market Concentration Ratio
3.4.1 Global Non-oncology Biopharmaceuticals Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-oncology Biopharmaceuticals Revenue in 2020
3.5 Non-oncology Biopharmaceuticals Key Players Head office and Area Served
3.6 Key Players Non-oncology Biopharmaceuticals Product Solution and Service
3.7 Date of Enter into Non-oncology Biopharmaceuticals Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Non-oncology Biopharmaceuticals Breakdown Data by Type
4.1 Global Non-oncology Biopharmaceuticals Historic Market Size by Type (2016-2021)
4.2 Global Non-oncology Biopharmaceuticals Forecasted Market Size by Type (2022-2027)

5 Non-oncology Biopharmaceuticals Breakdown Data by Application
5.1 Global Non-oncology Biopharmaceuticals Historic Market Size by Application (2016-2021)
5.2 Global Non-oncology Biopharmaceuticals Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Non-oncology Biopharmaceuticals Market Size (2016-2027)
6.2 North America Non-oncology Biopharmaceuticals Market Size by Type
6.2.1 North America Non-oncology Biopharmaceuticals Market Size by Type (2016-2021)
6.2.2 North America Non-oncology Biopharmaceuticals Market Size by Type (2022-2027)
6.2.3 North America Non-oncology Biopharmaceuticals Market Size by Type (2016-2027)
6.3 North America Non-oncology Biopharmaceuticals Market Size by Application
6.3.1 North America Non-oncology Biopharmaceuticals Market Size by Application (2016-2021)
6.3.2 North America Non-oncology Biopharmaceuticals Market Size by Application (2022-2027)
6.3.3 North America Non-oncology Biopharmaceuticals Market Size by Application (2016-2027)
6.4 North America Non-oncology Biopharmaceuticals Market Size by Country
6.4.1 North America Non-oncology Biopharmaceuticals Market Size by Country (2016-2021)
6.4.2 North America Non-oncology Biopharmaceuticals Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Non-oncology Biopharmaceuticals Market Size (2016-2027)
7.2 Europe Non-oncology Biopharmaceuticals Market Size by Type
7.2.1 Europe Non-oncology Biopharmaceuticals Market Size by Type (2016-2021)
7.2.2 Europe Non-oncology Biopharmaceuticals Market Size by Type (2022-2027)
7.2.3 Europe Non-oncology Biopharmaceuticals Market Size by Type (2016-2027)
7.3 Europe Non-oncology Biopharmaceuticals Market Size by Application
7.3.1 Europe Non-oncology Biopharmaceuticals Market Size by Application (2016-2021)
7.3.2 Europe Non-oncology Biopharmaceuticals Market Size by Application (2022-2027)
7.3.3 Europe Non-oncology Biopharmaceuticals Market Size by Application (2016-2027)
7.4 Europe Non-oncology Biopharmaceuticals Market Size by Country
7.4.1 Europe Non-oncology Biopharmaceuticals Market Size by Country (2016-2021)
7.4.2 Europe Non-oncology Biopharmaceuticals Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Non-oncology Biopharmaceuticals Market Size (2016-2027)
8.2 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Type
8.2.1 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Type (2016-2027)
8.3 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Application
8.3.1 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Application (2016-2027)
8.4 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Region
8.4.1 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Non-oncology Biopharmaceuticals Market Size (2016-2027)
9.2 Latin America Non-oncology Biopharmaceuticals Market Size by Type
9.2.1 Latin America Non-oncology Biopharmaceuticals Market Size by Type (2016-2021)
9.2.2 Latin America Non-oncology Biopharmaceuticals Market Size by Type (2022-2027)
9.2.3 Latin America Non-oncology Biopharmaceuticals Market Size by Type (2016-2027)
9.3 Latin America Non-oncology Biopharmaceuticals Market Size by Application
9.3.1 Latin America Non-oncology Biopharmaceuticals Market Size by Application (2016-2021)
9.3.2 Latin America Non-oncology Biopharmaceuticals Market Size by Application (2022-2027)
9.3.3 Latin America Non-oncology Biopharmaceuticals Market Size by Application (2016-2027)
9.4 Latin America Non-oncology Biopharmaceuticals Market Size by Country
9.4.1 Latin America Non-oncology Biopharmaceuticals Market Size by Country (2016-2021)
9.4.2 Latin America Non-oncology Biopharmaceuticals Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Non-oncology Biopharmaceuticals Market Size (2016-2027)
10.2 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Type
10.2.1 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Type (2016-2027)
10.3 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Application
10.3.1 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Application (2016-2027)
10.4 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Country
10.4.1 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Roche Business Overview
11.1.3 Roche Non-oncology Biopharmaceuticals Introduction
11.1.4 Roche Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
11.1.5 Roche Recent Development
11.2 Sanofi
11.2.1 Sanofi Company Details
11.2.2 Sanofi Business Overview
11.2.3 Sanofi Non-oncology Biopharmaceuticals Introduction
11.2.4 Sanofi Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
11.2.5 Sanofi Recent Development
11.3 Johnson & Johnson
11.3.1 Johnson & Johnson Company Details
11.3.2 Johnson & Johnson Business Overview
11.3.3 Johnson & Johnson Non-oncology Biopharmaceuticals Introduction
11.3.4 Johnson & Johnson Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
11.3.5 Johnson & Johnson Recent Development
11.4 Pfizer
11.4.1 Pfizer Company Details
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Non-oncology Biopharmaceuticals Introduction
11.4.4 Pfizer Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
11.4.5 Pfizer Recent Development
11.5 Novo Nordisk
11.5.1 Novo Nordisk Company Details
11.5.2 Novo Nordisk Business Overview
11.5.3 Novo Nordisk Non-oncology Biopharmaceuticals Introduction
11.5.4 Novo Nordisk Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
11.5.5 Novo Nordisk Recent Development
11.6 Novartis
11.6.1 Novartis Company Details
11.6.2 Novartis Business Overview
11.6.3 Novartis Non-oncology Biopharmaceuticals Introduction
11.6.4 Novartis Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
11.6.5 Novartis Recent Development
11.7 Merck
11.7.1 Merck Company Details
11.7.2 Merck Business Overview
11.7.3 Merck Non-oncology Biopharmaceuticals Introduction
11.7.4 Merck Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
11.7.5 Merck Recent Development
11.8 Teva
11.8.1 Teva Company Details
11.8.2 Teva Business Overview
11.8.3 Teva Non-oncology Biopharmaceuticals Introduction
11.8.4 Teva Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
11.8.5 Teva Recent Development
11.9 Eli Lilly
11.9.1 Eli Lilly Company Details
11.9.2 Eli Lilly Business Overview
11.9.3 Eli Lilly Non-oncology Biopharmaceuticals Introduction
11.9.4 Eli Lilly Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
11.9.5 Eli Lilly Recent Development
11.10 Bristol-Myers Squibb
11.10.1 Bristol-Myers Squibb Company Details
11.10.2 Bristol-Myers Squibb Business Overview
11.10.3 Bristol-Myers Squibb Non-oncology Biopharmaceuticals Introduction
11.10.4 Bristol-Myers Squibb Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
11.10.5 Bristol-Myers Squibb Recent Development
11.11 GlaxoSmithKline
11.11.1 GlaxoSmithKline Company Details
11.11.2 GlaxoSmithKline Business Overview
11.11.3 GlaxoSmithKline Non-oncology Biopharmaceuticals Introduction
11.11.4 GlaxoSmithKline Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
11.11.5 GlaxoSmithKline Recent Development
11.12 UCB Pharma
11.12.1 UCB Pharma Company Details
11.12.2 UCB Pharma Business Overview
11.12.3 UCB Pharma Non-oncology Biopharmaceuticals Introduction
11.12.4 UCB Pharma Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
11.12.5 UCB Pharma Recent Development
11.13 Amgen
11.13.1 Amgen Company Details
11.13.2 Amgen Business Overview
11.13.3 Amgen Non-oncology Biopharmaceuticals Introduction
11.13.4 Amgen Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
11.13.5 Amgen Recent Development
11.14 AbbVie
11.14.1 AbbVie Company Details
11.14.2 AbbVie Business Overview
11.14.3 AbbVie Non-oncology Biopharmaceuticals Introduction
11.14.4 AbbVie Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
11.14.5 AbbVie Recent Development
11.15 Takeda
11.15.1 Takeda Company Details
11.15.2 Takeda Business Overview
11.15.3 Takeda Non-oncology Biopharmaceuticals Introduction
11.15.4 Takeda Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
11.15.5 Takeda Recent Development
11.16 AstraZeneca
11.16.1 AstraZeneca Company Details
11.16.2 AstraZeneca Business Overview
11.16.3 AstraZeneca Non-oncology Biopharmaceuticals Introduction
11.16.4 AstraZeneca Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
11.16.5 AstraZeneca Recent Development
11.17 Mylan
11.17.1 Mylan Company Details
11.17.2 Mylan Business Overview
11.17.3 Mylan Non-oncology Biopharmaceuticals Introduction
11.17.4 Mylan Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
11.17.5 Mylan Recent Development
11.18 LEO Pharma
11.18.1 LEO Pharma Company Details
11.18.2 LEO Pharma Business Overview
11.18.3 LEO Pharma Non-oncology Biopharmaceuticals Introduction
11.18.4 LEO Pharma Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
11.18.5 LEO Pharma Recent Development
11.18 Boehringer Ingelheim
.1 Boehringer Ingelheim Company Details
.2 Boehringer Ingelheim Business Overview
.3 Boehringer Ingelheim Non-oncology Biopharmaceuticals Introduction
.4 Boehringer Ingelheim Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
.5 Boehringer Ingelheim Recent Development
11.20 Alexion Pharmaceuticals
11.20.1 Alexion Pharmaceuticals Company Details
11.20.2 Alexion Pharmaceuticals Business Overview
11.20.3 Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Introduction
11.20.4 Alexion Pharmaceuticals Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
11.20.5 Alexion Pharmaceuticals Recent Development
11.21 Elusys Therapeutics
11.21.1 Elusys Therapeutics Company Details
11.21.2 Elusys Therapeutics Business Overview
11.21.3 Elusys Therapeutics Non-oncology Biopharmaceuticals Introduction
11.21.4 Elusys Therapeutics Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
11.21.5 Elusys Therapeutics Recent Development
11.22 Swedish Orphan Biovitrum
11.22.1 Swedish Orphan Biovitrum Company Details
11.22.2 Swedish Orphan Biovitrum Business Overview
11.22.3 Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Introduction
11.22.4 Swedish Orphan Biovitrum Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
11.22.5 Swedish Orphan Biovitrum Recent Development
11.23 Biogen
11.23.1 Biogen Company Details
11.23.2 Biogen Business Overview
11.23.3 Biogen Non-oncology Biopharmaceuticals Introduction
11.23.4 Biogen Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
11.23.5 Biogen Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Non-oncology Biopharmaceuticals Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Biologics
Table 3. Key Players of Biosimilars
Table 4. Global Non-oncology Biopharmaceuticals Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 5. Global Non-oncology Biopharmaceuticals Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Non-oncology Biopharmaceuticals Market Size by Regions (2016-2021) & (US$ Million)
Table 7. Global Non-oncology Biopharmaceuticals Market Share by Regions (2016-2021)
Table 8. Global Non-oncology Biopharmaceuticals Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 9. Global Non-oncology Biopharmaceuticals Market Share by Regions (2022-2027)
Table 10. Non-oncology Biopharmaceuticals Market Trends
Table 11. Non-oncology Biopharmaceuticals Market Drivers
Table 12. Non-oncology Biopharmaceuticals Market Challenges
Table 13. Non-oncology Biopharmaceuticals Market Restraints
Table 14. Global Non-oncology Biopharmaceuticals Revenue by Players (2016-2021) & (US$ Million)
Table 15. Global Non-oncology Biopharmaceuticals Market Share by Players (2016-2021)
Table 16. Global Top Non-oncology Biopharmaceuticals Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non-oncology Biopharmaceuticals as of 2020)
Table 17. Ranking of Global Top Non-oncology Biopharmaceuticals Companies by Revenue (US$ Million) in 2020
Table 18. Global 5 Largest Players Market Share by Non-oncology Biopharmaceuticals Revenue (CR5 and HHI) & (2016-2021)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Non-oncology Biopharmaceuticals Product Solution and Service
Table 21. Date of Enter into Non-oncology Biopharmaceuticals Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Non-oncology Biopharmaceuticals Market Size by Type (2016-2021) (US$ Million)
Table 24. Global Non-oncology Biopharmaceuticals Revenue Market Share by Type (2016-2021)
Table 25. Global Non-oncology Biopharmaceuticals Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 26. Global Non-oncology Biopharmaceuticals Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 27. Global Non-oncology Biopharmaceuticals Market Size Share by Application (2016-2021) & (US$ Million)
Table 28. Global Non-oncology Biopharmaceuticals Revenue Market Share by Application (2016-2021)
Table 29. Global Non-oncology Biopharmaceuticals Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 30. Global Non-oncology Biopharmaceuticals Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 31. North America Non-oncology Biopharmaceuticals Market Size by Type (2016-2021) (US$ Million)
Table 32. North America Non-oncology Biopharmaceuticals Market Size by Type (2022-2027) & (US$ Million)
Table 33. North America Non-oncology Biopharmaceuticals Market Size by Application (2016-2021) (US$ Million)
Table 34. North America Non-oncology Biopharmaceuticals Market Size by Application (2022-2027) & (US$ Million)
Table 35. North America Non-oncology Biopharmaceuticals Market Size by Country (2016-2021) & (US$ Million)
Table 36. North America Non-oncology Biopharmaceuticals Market Size by Country (2022-2027) & (US$ Million)
Table 37. Europe Non-oncology Biopharmaceuticals Market Size by Type (2016-2021) (US$ Million)
Table 38. Europe Non-oncology Biopharmaceuticals Market Size by Type (2022-2027) & (US$ Million)
Table 39. Europe Non-oncology Biopharmaceuticals Market Size by Application (2016-2021) (US$ Million)
Table 40. Europe Non-oncology Biopharmaceuticals Market Size by Application (2022-2027) & (US$ Million)
Table 41. Europe Non-oncology Biopharmaceuticals Market Size by Country (2016-2021) & (US$ Million)
Table 42. Europe Non-oncology Biopharmaceuticals Market Size by Country (2022-2027) & (US$ Million)
Table 43. Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Type (2016-2021) (US$ Million)
Table 44. Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Type (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Application (2016-2021) (US$ Million)
Table 46. Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Application (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Region (2016-2021) & (US$ Million)
Table 48. Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Region (2022-2027) & (US$ Million)
Table 49. Latin America Non-oncology Biopharmaceuticals Market Size by Type (2016-2021) (US$ Million)
Table 50. Latin America Non-oncology Biopharmaceuticals Market Size by Type (2022-2027) & (US$ Million)
Table 51. Latin America Non-oncology Biopharmaceuticals Market Size by Application (2016-2021) (US$ Million)
Table 52. Latin America Non-oncology Biopharmaceuticals Market Size by Application (2022-2027) & (US$ Million)
Table 53. Latin America Non-oncology Biopharmaceuticals Market Size by Country (2016-2021) & (US$ Million)
Table 54. Latin America Non-oncology Biopharmaceuticals Market Size by Country (2022-2027) & (US$ Million)
Table 55. Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Type (2016-2021) (US$ Million)
Table 56. Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Type (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Application (2016-2021) (US$ Million)
Table 58. Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Application (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Country (2016-2021) & (US$ Million)
Table 60. Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Country (2022-2027) & (US$ Million)
Table 61. Roche Company Details
Table 62. Roche Business Overview
Table 63. Roche Non-oncology Biopharmaceuticals Product
Table 64. Roche Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 65. Roche Recent Development
Table 66. Sanofi Company Details
Table 67. Sanofi Business Overview
Table 68. Sanofi Non-oncology Biopharmaceuticals Product
Table 69. Sanofi Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 70. Sanofi Recent Development
Table 71. Johnson & Johnson Company Details
Table 72. Johnson & Johnson Business Overview
Table 73. Johnson & Johnson Non-oncology Biopharmaceuticals Product
Table 74. Johnson & Johnson Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 75. Johnson & Johnson Recent Development
Table 76. Pfizer Company Details
Table 77. Pfizer Business Overview
Table 78. Pfizer Non-oncology Biopharmaceuticals Product
Table 79. Pfizer Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 80. Pfizer Recent Development
Table 81. Novo Nordisk Company Details
Table 82. Novo Nordisk Business Overview
Table 83. Novo Nordisk Non-oncology Biopharmaceuticals Product
Table 84. Novo Nordisk Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 85. Novo Nordisk Recent Development
Table 86. Novartis Company Details
Table 87. Novartis Business Overview
Table 88. Novartis Non-oncology Biopharmaceuticals Product
Table 89. Novartis Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 90. Novartis Recent Development
Table 91. Merck Company Details
Table 92. Merck Business Overview
Table 93. Merck Non-oncology Biopharmaceuticals Product
Table 94. Merck Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 95. Merck Recent Development
Table 96. Teva Company Details
Table 97. Teva Business Overview
Table 98. Teva Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 99. Teva Recent Development
Table 100. Eli Lilly Company Details
Table 101. Eli Lilly Business Overview
Table 102. Eli Lilly Non-oncology Biopharmaceuticals Product
Table 103. Eli Lilly Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 104. Eli Lilly Recent Development
Table 105. Bristol-Myers Squibb Company Details
Table 106. Bristol-Myers Squibb Business Overview
Table 107. Bristol-Myers Squibb Non-oncology Biopharmaceuticals Product
Table 108. Bristol-Myers Squibb Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 109. Bristol-Myers Squibb Recent Development
Table 110. GlaxoSmithKline Company Details
Table 111. GlaxoSmithKline Business Overview
Table 112. GlaxoSmithKline Non-oncology Biopharmaceuticals Product
Table 113. GlaxoSmithKline Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 114. GlaxoSmithKline Recent Development
Table 115. UCB Pharma Company Details
Table 116. UCB Pharma Business Overview
Table 117. UCB Pharma Non-oncology Biopharmaceuticals Product
Table 118. UCB Pharma Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 119. UCB Pharma Recent Development
Table 120. Amgen Company Details
Table 121. Amgen Business Overview
Table 122. Amgen Non-oncology Biopharmaceuticals Product
Table 123. Amgen Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 124. Amgen Recent Development
Table 125. AbbVie Company Details
Table 126. AbbVie Business Overview
Table 127. AbbVie Non-oncology Biopharmaceuticals Product
Table 128. AbbVie Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 129. AbbVie Recent Development
Table 130. Takeda Company Details
Table 131. Takeda Business Overview
Table 132. Takeda Non-oncology Biopharmaceuticals Product
Table 133. Takeda Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 134. Takeda Recent Development
Table 135. AstraZeneca Company Details
Table 136. AstraZeneca Business Overview
Table 137. AstraZeneca Non-oncology Biopharmaceuticals Product
Table 138. AstraZeneca Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 139. AstraZeneca Recent Development
Table 140. Mylan Company Details
Table 141. Mylan Business Overview
Table 142. Mylan Non-oncology Biopharmaceuticals Product
Table 143. Mylan Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 144. Mylan Recent Development
Table 145. LEO Pharma Company Details
Table 146. LEO Pharma Business Overview
Table 147. LEO Pharma Non-oncology Biopharmaceuticals Product
Table 148. LEO Pharma Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 149. LEO Pharma Recent Development
Table 150. Boehringer Ingelheim Company Details
Table 151. Boehringer Ingelheim Business Overview
Table 152. Boehringer Ingelheim Non-oncology Biopharmaceuticals Product
Table 153. Boehringer Ingelheim Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 154. Boehringer Ingelheim Recent Development
Table 155. Alexion Pharmaceuticals Company Details
Table 156. Alexion Pharmaceuticals Business Overview
Table 157. Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Product
Table 158. Alexion Pharmaceuticals Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 159. Alexion Pharmaceuticals Recent Development
Table 160. Elusys Therapeutics Company Details
Table 161. Elusys Therapeutics Business Overview
Table 162. Elusys Therapeutics Non-oncology Biopharmaceuticals Product
Table 163. Elusys Therapeutics Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 164. Elusys Therapeutics Recent Development
Table 165. Swedish Orphan Biovitrum Company Details
Table 166. Swedish Orphan Biovitrum Business Overview
Table 167. Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Product
Table 168. Swedish Orphan Biovitrum Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 169. Swedish Orphan Biovitrum Recent Development
Table 170. Biogen Company Details
Table 171. Biogen Business Overview
Table 172. Biogen Non-oncology Biopharmaceuticals Product
Table 173. Biogen Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 174. Biogen Recent Development
Table 175. Research Programs/Design for This Report
Table 176. Key Data Information from Secondary Sources
Table 177. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Non-oncology Biopharmaceuticals Market Share by Type: 2020 VS 2027
Figure 2. Biologics Features
Figure 3. Biosimilars Features
Figure 4. Global Non-oncology Biopharmaceuticals Market Share by Application: 2020 VS 2027
Figure 5. Immunology Case Studies
Figure 6. Endocrinology Case Studies
Figure 7. Others Case Studies
Figure 8. Non-oncology Biopharmaceuticals Report Years Considered
Figure 9. Global Non-oncology Biopharmaceuticals Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 10. Global Non-oncology Biopharmaceuticals Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 11. Global Non-oncology Biopharmaceuticals Market Share by Regions: 2020 VS 2027
Figure 12. Global Non-oncology Biopharmaceuticals Market Share by Regions (2022-2027)
Figure 13. Global Non-oncology Biopharmaceuticals Market Share by Players in 2020
Figure 14. Global Top Non-oncology Biopharmaceuticals Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non-oncology Biopharmaceuticals as of 2020
Figure 15. The Top 10 and 5 Players Market Share by Non-oncology Biopharmaceuticals Revenue in 2020
Figure 16. Global Non-oncology Biopharmaceuticals Revenue Market Share by Type (2016-2021)
Figure 17. Global Non-oncology Biopharmaceuticals Revenue Market Share by Type (2022-2027)
Figure 18. North America Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 19. North America Non-oncology Biopharmaceuticals Market Share by Type (2016-2027)
Figure 20. North America Non-oncology Biopharmaceuticals Market Share by Application (2016-2027)
Figure 21. North America Non-oncology Biopharmaceuticals Market Share by Country (2016-2027)
Figure 22. United States Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. Canada Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Europe Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Non-oncology Biopharmaceuticals Market Share by Type (2016-2027)
Figure 26. Europe Non-oncology Biopharmaceuticals Market Share by Application (2016-2027)
Figure 27. Europe Non-oncology Biopharmaceuticals Market Share by Country (2016-2027)
Figure 28. Germany Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. France Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. U.K. Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Italy Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Russia Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Nordic Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Asia-Pacific Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Non-oncology Biopharmaceuticals Market Share by Type (2016-2027)
Figure 36. Asia-Pacific Non-oncology Biopharmaceuticals Market Share by Application (2016-2027)
Figure 37. Asia-Pacific Non-oncology Biopharmaceuticals Market Share by Region (2016-2027)
Figure 38. China Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Japan Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. South Korea Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Southeast Asia Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. India Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Australia Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Latin America Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Non-oncology Biopharmaceuticals Market Share by Type (2016-2027)
Figure 46. Latin America Non-oncology Biopharmaceuticals Market Share by Application (2016-2027)
Figure 47. Latin America Non-oncology Biopharmaceuticals Market Share by Country (2016-2027)
Figure 48. Mexico Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Brazil Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Middle East & Africa Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Non-oncology Biopharmaceuticals Market Share by Type (2016-2027)
Figure 52. Middle East & Africa Non-oncology Biopharmaceuticals Market Share by Application (2016-2027)
Figure 53. Middle East & Africa Non-oncology Biopharmaceuticals Market Share by Country (2016-2027)
Figure 54. Turkey Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Saudi Arabia Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. UAE Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Roche Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021)
Figure 58. Sanofi Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021)
Figure 59. Johnson & Johnson Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021)
Figure 60. Pfizer Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021)
Figure 61. Novo Nordisk Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021)
Figure 62. Novartis Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021)
Figure 63. Merck Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021)
Figure 64. Teva Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021)
Figure 65. Eli Lilly Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021)
Figure 66. Bristol-Myers Squibb Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021)
Figure 67. GlaxoSmithKline Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021)
Figure 68. UCB Pharma Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021)
Figure 69. Amgen Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021)
Figure 70. AbbVie Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021)
Figure 71. Takeda Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021)
Figure 72. AstraZeneca Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021)
Figure 73. Mylan Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021)
Figure 74. LEO Pharma Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021)
Figure 75. Boehringer Ingelheim Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021)
Figure 76. Alexion Pharmaceuticals Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021)
Figure 77. Elusys Therapeutics Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021)
Figure 78. Swedish Orphan Biovitrum Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021)
Figure 79. Biogen Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021)
Figure 80. Bottom-up and Top-down Approaches for This Report
Figure 81. Data Triangulation
Figure 82. Key Executives Interviewed

以下、関連資料のご紹介

世界のがんバイオ医薬品市場規模・現状・予測（2021年-2027年）

Global Cancer Biopharmaceuticals Market Size, Status and Forecast 2021-2027
QFJ1-5641 2021年6月 118Pages
QYResearch社発行の本調査レポートでは、がんバイオ医薬品の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（生物製剤、バイオシミラー）、用途別市場規模（液状がん、固形がん）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、イ...

世界のバイオ医薬品製造消耗品試験市場規模・現状・予測（2021年-2027年）

Global Biopharmaceuticals Manufacturing Consumables Testing Market Size, Status and Forecast 2021-2027
QFJ1-3910 2021年6月 100Pages
QYResearch社発行の本調査レポートでは、バイオ医薬品製造消耗品試験の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（化学分析試験、酵素試験、安定性試験、滅菌試験、その他）、用途別市場規模（医薬品＆バイオ、医療機器、その他）、主要地域別市場規模...

世界のバイオ医薬品受託製造市場規模・現状・予測（2021年-2027年）

Global Biopharmaceuticals Contract Manufacturing Market Size, Status and Forecast 2021-2027
QFJ1-5620 2021年6月 107Pages
QYResearch社発行の本調査レポートでは、バイオ医薬品受託製造の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（生物製剤、バイオシミラー）、用途別市場規模（プロセス開発、包装、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中...

世界の免疫腫瘍学アッセイ市場規模・現状・予測（2021年-2027年）

Global Immuno Oncology Assays Market Size, Status and Forecast 2021-2027
QFJ1-4349 2021年6月 85Pages
QYResearch社発行の本調査レポートでは、免疫腫瘍学アッセイの世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（イムノアッセイ、フローサイトメトリー、PCR、次世代シーケンシング）、用途別市場規模（研究所、臨床診断）、主要地域別市場規模（北米、ア...

世界の腫瘍血液検査市場規模・現状・予測（2021年-2027年）

Global Oncology Blood Testing Market Size, Status and Forecast 2021-2027
QFJ1-4605 2021年6月 95Pages
QYResearch社発行の本調査レポートでは、腫瘍血液検査の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（肺がん、乳がん、結腸直腸がん、前立腺がん、胃がん、その）、用途別市場規模（病院、クリニック、外来手術センター）、主要地域別市場規模（北米、ア...

世界の転移性結腸直腸癌治療市場規模・現状・予測（2021年-2027年）

Global Metastatic Colorectal Cancer Treatment Market Size, Status and Forecast 2021-2027
QFJ1-4497 2021年6月 106Pages
QYResearch社発行の本調査レポートでは、転移性結腸直腸癌治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（外科、化学療法）、用途別市場規模（病院、クリニック、がん研究センター）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国...

世界の前臨床オンコロジーCRO市場規模・現状・予測（2021年-2027年）

Global Preclinical Oncology CRO Market Size, Status and Forecast 2021-2027
QFJ1-4747 2021年6月 108Pages
QYResearch社発行の本調査レポートでは、前臨床オンコロジーCROの世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（血液がん、固形腫瘍、その他）、用途別市場規模（In Vitro、In Vivo）、主要地域別市場規模（北米、アメリカ、欧州、アジ...

世界のジェネリック腫瘍薬市場規模・現状・予測（2021年-2027年）

Global Generic Oncology Drugs Market Size, Status and Forecast 2021-2027
QFJ1-4251 2021年6月 109Pages
QYResearch社発行の本調査レポートでは、ジェネリック腫瘍薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（高分子薬、小分子薬）、用途別市場規模（病院薬局、小売薬局、オンライン薬局）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中...

世界の腫瘍バイオマーカー市場規模・現状・予測（2021年-2027年）

Global Oncology Biomarker Market Size, Status and Forecast 2021-2027
QFJ1-4604 2021年6月 105Pages
QYResearch社発行の本調査レポートでは、腫瘍バイオマーカーの世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（血液がん、固形腫瘍、その他）、用途別市場規模（診断、創薬・開発、予後、リスクアセスメント、その他）、主要地域別市場規模（北米、アメリカ...

世界の血液腫瘍学検査市場規模・現状・予測（2021年-2027年）

Global Hemato Oncology Testing Market Size, Status and Forecast 2021-2027
QFJ1-5189 2021年6月 109Pages
QYResearch社発行の本調査レポートでは、血液腫瘍学検査の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（白血病検査、急性骨髄性検査、多発性骨髄腫検査、その他）、用途別市場規模（臨床検査室、病院）、主要地域別市場規模（北米、アメリカ、欧州、アジ...

世界のバイオ医薬品受託製造市場規模・現状・予測（2021年-2027年） Contract manufacturing organization is a company that serve other companies in the biopharmaceutical industry on a contract basis to provide comprehensive services from drug development through drug manufacturing. Market Analysis and Insights: Global Biopharmaceuticals Contract Manufacturing Market …
世界のがんバイオ医薬品市場規模・現状・予測（2021年-2027年） Biopharmaceutical, also known as a biologic (al) medical product, biological, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semi synthesized from biological sources. Cancer is a complex invasive genetic disease that causes significant mortality rate worldwide. C…
世界のバイオ医薬品製造消耗品試験市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Biopharmaceuticals Manufacturing Consumables Testing Market The global Biopharmaceuticals Manufacturing Consumables Testing market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-sta…
世界の免疫腫瘍学アッセイ市場規模・現状・予測（2021年-2027年） Immuno-Oncology Assays Accelerate Cancer Immunotherapy enable fast, effective, and clinically relevant understanding of immuno-oncology targets, pathways and mechanisms, enabling quicker development of immuno-oncology drugs. Learn how you can rapidly screen and develop antibodies targeting checkpoin…
世界の転移性結腸直腸癌治療市場規模・現状・予測（2021年-2027年） Colorectal cancer is the third most common type cancer and represents 9.7% of total cancer cases across the globe. According to American Cancer Society colorectal cancer is treatable and curable when it is localized to the bowel. However, colorectal cancer cancers that have spread to other body part…